Sadhana Jackson, M.D.

Assistant Clinical Investigator

Neuro-Oncology Branch


Building 82, Room 227
Bethesda, MD 20892


Research Topics

One of the major obstacles to effectively treating central nervous system (CNS) disease is the integrity of the blood-brain barrier (BBB).  The BBB prevents delivery of systemic drugs to the brain and tumor tissue.  While previous studies have focused on circumventing the BBB using direct tumor delivery, and mechanically opening the BBB, very few agents have been evaluated for effectiveness of BBB disruption in an effort to increase drug entry to the brain. 

My research area focuses on understanding the blood-brain barrier and blood-tumor barrier in malignant gliomas.  My laboratory studies pertain to comprehensive evaluation of BBB biology by analysis of the genomics, proteomics and pharmacokinetics.  These in vitro and preclinical studies assess BBB characteristics in both normal and diseased brain.  These findings will then be translated to clinical trials to evaluate the utility of varied pharmacologic agents to transiently open the BBB to improve chemotherapeutic delivery. 


Dr. Jackson received her medical doctorate (M.D.) degree in medicine from Eastern Virginia Medical School (EVMS) in 2007.  She completed her residency at Orlando Health in pediatrics in 2010.  In 2013, she completed her pediatric hematology/oncology fellowship at St. Jude Children’s Hospital (SJCRH).  Then she concluded her training at Johns Hopkins in 2015 in concurrent pediatric neuro-oncology and clinical pharmacology fellowships.

Selected Publications

  1. Jackson S, Anders NM, Mangraviti A, Wanjiku TM, Sankey EW, Liu A, Brem H, Tyler B, Rudek MA, Grossman SA. The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. J Neurooncol. 2016;126(3):433-9.

  2. Morfouace M, Cheepala S, Jackson S, Fukuda Y, Patel YT, Fatima S, Kawauchi D, Shelat AA, Stewart CF, Sorrentino BP, Schuetz JD, Roussel MF. ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy. Cancer Res. 2015;75(18):3879-89.

  3. Rodriguez FJ, Tihan T, Lin D, McDonald W, Nigro J, Feuerstein B, Jackson S, Cohen K, Burger PC. Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients. Am J Surg Pathol. 2014;38(8):1058-70.

  4. Jackson S, Patay Z, Howarth R, Pai Panandiker AS, Onar-Thomas A, Gajjar A, Broniscer A. Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma. J Neurooncol. 2013;114(3):339-44.

This page was last updated on May 1st, 2019